At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

GLP-1 receptor agonists, initially developed for type 2 diabetes, have gained traction for weight loss and cardiovascular risk reduction. However, doctors say their use in type 1 diabetes patients ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

“While assessments of medical records and registries have not suggested increased risk of suicide or self-harm with GLP-1 receptor agonist use, these data are not ideal to answer this question ...